July 16, 2013
Hisamitsu Pharmaceutical announced on July 10 that it has started a domestic PII study of the long-acting transdermal allergic rhinitis treatment HP-3060 (development code). The company only revealed that HP-3060 contains existing ingredients. If approved, HP-3060 will be the world’s...read more